Author’s reply to correspondence on “Expanding the Use of HIPEC in Ovarian Cancer at Interval Debulking Surgery to FIGO Stage IV and After 6 Cycles of Neoadjuvant Chemotherapy: A Prospective Analysis and Perioperative and Oncologic Outcomes” by Mukurdipi Ray et al.
